Hydrocortisone Use During Peri-operation for Pituitary Adenomas

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose hypothalamus pituitary adrenal axis are intact are safe.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate

Criteria

Inclusion Criteria:

• Patients with pituitary adenomas that need surgical resection of the tumor, whose hypothalamus-pituitary-adrenal axis are intact

• Patients of either gender aged from 18 years to 70 years

Exclusion Criteria:

• Patients with Cushing's disease

• Patients with pituitary adenomas who have already developed secondary adrenal insufficiency before surgery

• Patients with pituitary apoplexy or other acute pituitary conditions that need emergency surgery

• The postoperative pathology result indicates that the tumor is not a pituitary adenoma

• Patients that refuse to participate in the study or those who ask to quit after enrollment